Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...

Acute Coronary Syndrome IV: Interprofessional Care

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.

The New England journal of medicine·2018

Same author

Outcomes of Patients Receiving Downstream Revascularization After Initial Medical Management for Non-ST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial).

The American journal of cardiology·2018

Same author

In the transition from fibrinolysis to primary PCI, the HERO trials help refine STEMI ECG interpretation and Q wave analysis potentially alters future management.

European heart journal. Acute cardiovascular care·2018

Same author

Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials.

International journal of cardiology·2018

Same author

Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS.

Diabetes, obesity & metabolism·2018

Same author

Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarction.

American heart journal·2018

Search research articles

Related Experiment Video

Updated: Jun 5, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Antithrombotic therapy in ST-segment elevation myocardial infarction.

Cheuk-Kit Wong¹, Harvey D White

¹University of Otago, Dunedin School of Medicine, New Zealand.

Expert Opinion on Pharmacotherapy

|January 14, 2011

Summary

Optimizing anticoagulation in ST-segment elevation myocardial infarction (STEMI) involves balancing clot prevention and bleeding risk. Newer agents like P2Y12 inhibitors and bivalirudin offer improved outcomes compared to older treatments.

More Related Videos

Prehospital Thrombolysis: A Manual from Berlin

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

Related Experiment Videos

Last Updated: Jun 5, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Prehospital Thrombolysis: A Manual from Berlin

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

Area of Science:

Cardiology
Pharmacology

Background:

Anticoagulation is crucial for reperfusion therapies in ST-segment elevation myocardial infarction (STEMI).
Balancing thrombotic complications and bleeding risk is complex.

Purpose of the Study:

To review current anticoagulation strategies for STEMI.
To discuss the efficacy and safety of various antiplatelet and anticoagulant agents.

Main Methods:

Review of adjunctive anticoagulation regimens in fibrinolytic therapy and percutaneous coronary intervention (PCI).
Comparison of newer P2Y12 inhibitors (prasugrel, ticagrelor) and glycoprotein IIb/IIIa inhibitors.
Evaluation of enoxaparin and bivalirudin versus unfractionated heparin (UFH).

Main Results:

Newer P2Y12 inhibitors reduce cardiovascular death, MI, stroke, and stent thrombosis compared to clopidogrel; ticagrelor also reduces mortality.
Enoxaparin shows benefits over UFH in fibrinolytic therapy and trends towards reduced bleeding in primary PCI.
Bivalirudin reduces bleeding and mortality compared to UFH plus glycoprotein IIb/IIIa inhibitors in primary PCI.

Conclusions:

The field of anticoagulation for STEMI is rapidly evolving.
Multiple therapeutic approaches exist, requiring careful consideration of individual patient risks and benefits.